| 12/06/25 | GSK | 11:00:00 | 12 Jun 2025 | | GSK | Director/PDMR Shareholding | GSK plc | PRN |
| 24/10/24 | GSK | 07:00:08 | 24 Oct 2024 | | GSK | New positive Arexvy data in younger adults at risk | GSK PLC | RNS |
| 17/10/24 | GSK | 15:30:01 | 17 Oct 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 16/10/24 | GSK | 16:09:21 | 16 Oct 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 16/10/24 | GSK | 07:00:02 | 16 Oct 2024 | | GSK | FDA accepts new drug application for gepotidacin | GSK PLC | RNS |
| 14/10/24 | GSK | 15:30:01 | 14 Oct 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 14/10/24 | GSK | 07:00:05 | 14 Oct 2024 | | GSK | Positive results of ANCHOR trials of depemokimab | GSK PLC | RNS |
| 11/10/24 | GSK | 15:33:56 | 11 Oct 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 10/10/24 | GSK | 15:30:00 | 10 Oct 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 09/10/24 | GSK | 17:48:56 | 9 Oct 2024 | | GSK | Zantac (ranitidine) litigation settlements | GSK PLC | RNS |
| 08/10/24 | GSK | 11:45:00 | 8 Oct 2024 | | GSK | Positive efficacy data of Arexvy over 3 seasons | GSK PLC | RNS |
| 01/10/24 | GSK | 15:00:01 | 1 Oct 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 24/09/24 | GSK | 15:30:00 | 24 Sept 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 24/09/24 | GSK | 07:00:03 | 24 Sept 2024 | | GSK | Positive EU opinion for GSK liquid Menveo vaccine | GSK PLC | RNS |
| 18/09/24 | GSK | 13:20:18 | 18 Sept 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 17/09/24 | GSK | 07:00:05 | 17 Sept 2024 | | GSK | Japan Filing Acceptance: Blenrep Multiple Myeloma | GSK PLC | RNS |
| 13/09/24 | GSK | 07:00:07 | 13 Sept 2024 | | GSK | China Breakthrough Therapy Designation for Blenrep | GSK PLC | RNS |
| 12/09/24 | GSK | 15:30:00 | 12 Sept 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/09/24 | GSK | 07:00:09 | 12 Sept 2024 | | GSK | Positive mRNA flu vaccine Phase II headline data | GSK PLC | RNS |
| 11/09/24 | GSK | 17:27:41 | 11 Sept 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 11/09/24 | GSK | 15:30:01 | 11 Sept 2024 | | GSK | Change of Registered Office | GSK PLC | RNS |
| 11/09/24 | GSK | 07:00:09 | 11 Sept 2024 | | GSK | Update on phase I/II therapeutic HSV vaccine trial | GSK PLC | RNS |
| 09/09/24 | GSK | 14:30:00 | 9 Sept 2024 | | GSK | Depemokimab late-breaking data presented at ERS | GSK PLC | RNS |
| 06/09/24 | GSK | 15:30:01 | 6 Sept 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 06/09/24 | GSK | 07:00:08 | 6 Sept 2024 | | GSK | Positive Phase III results for Nucala in COPD | GSK PLC | RNS |
| 02/09/24 | GSK | 15:00:00 | 2 Sept 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 29/08/24 | GSK | 07:00:04 | 29 Aug 2024 | | GSK | EMA approval on Arexvy for 50-59 at risk | GSK PLC | RNS |
| 28/08/24 | GSK | 07:10:01 | 28 Aug 2024 | | GSK | SENKU Designation for Bepirovirsen in Japan | GSK PLC | RNS |
| 28/08/24 | GSK | 07:05:00 | 28 Aug 2024 | | GSK | Nucala approved in Japan for use in CRSwNP | GSK PLC | RNS |
| 28/08/24 | GSK | 07:00:08 | 28 Aug 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 21/08/24 | GSK | 15:30:01 | 21 Aug 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 20/08/24 | GSK | 15:30:00 | 20 Aug 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 20/08/24 | GSK | 07:00:14 | 20 Aug 2024 | | GSK | B7-H3 ADC US FDA Breakthrough Therapy Designation | GSK PLC | RNS |
| 16/08/24 | GSK | 07:00:06 | 16 Aug 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 12/08/24 | GSK | 15:30:01 | 12 Aug 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 06/08/24 | GSK | 07:00:11 | 6 Aug 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 02/08/24 | GSK | 07:00:05 | 2 Aug 2024 | | GSK | FDA Expands Jemperli Approval | GSK PLC | RNS |
| 01/08/24 | GSK | 15:00:01 | 1 Aug 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 31/07/24 | GSK | 07:00:09 | 31 Jul 2024 | | GSK | 2nd Quarter Results | GSK PLC | RNS |
| 29/07/24 | GSK | 08:18:11 | 29 Jul 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 29/07/24 | GSK | 07:00:06 | 29 Jul 2024 | | GSK | CHMP positive opinion on Arexvy for 50-59 at risk | GSK PLC | RNS |
| 19/07/24 | GSK | 10:36:27 | 19 Jul 2024 | | GSK | Blenrep EMA Filing Acceptance | GSK PLC | RNS |
| 18/07/24 | GSK | 15:30:00 | 18 Jul 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 16/07/24 | GSK | 15:30:01 | 16 Jul 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 15/07/24 | GSK | 15:30:01 | 15 Jul 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 12/07/24 | GSK | 15:30:00 | 12 Jul 2024 | | GSK | Director/PDMR Shareholding | GSK PLC | RNS |
| 03/07/24 | GSK | 07:00:08 | 3 Jul 2024 | | GSK | GSK and CureVac collaboration restructured | GSK PLC | RNS |
| 01/07/24 | GSK | 15:00:01 | 1 Jul 2024 | | GSK | Total Voting Rights | GSK PLC | RNS |
| 28/06/24 | GSK | 17:37:19 | 28 Jun 2024 | | GSK | Statement: Zantac (ranitidine) litigation | GSK PLC | RNS |
| 24/06/24 | GSK | 07:05:00 | 24 Jun 2024 | | GSK | Omjjara approved in Japan for myelofibrosis | GSK PLC | RNS |
